PerkinElmer gets China marketing authorization on Genetic Screening system

China is to get its first access to an automatic screening system for genetic disorders in embryos after the CFDA cleared PerkinElmer's ($PKI) Genetic Screening Processor system, according to the U.S.-based company.

The maker of medical devices, with offices in Shanghai, said the screening system works with its reagent kit to analyze tests of neonatal dried-blood samples to detect disorders, including for congenital hypothyroidism.

PerkinElmer said the device was capable of testing for a wide range of disorders on a single platform. It said it also planned to introduce other GSP assays to China.

- here's the PerkinElmer release